Skip to main content

Table 2 Outcomes of thiopurine therapy in patients with or without TPMT polymorphisms

From: TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

  TPMT mutated
(N = 5)
n (%)/ Median (IQR)
Wild genotype
(N = 102)
n (%)/ Median (IQR)
p value
Hemoglobin (g/dL) at the end of follow up 10.8 (3.7) 11.05 (3.4) 0.983
Total leucocyte count (× 106/L) at the end of follow up 6340 (4200) 5700 (3575) 0.949
Platelet count (× 106/L) at end of follow up 312,000 (161,000) 254,000 (132,500) 0.983
Duration of thiopurine use (months) 12 (14.9) 8 (15.25) 0.348
Max tolerated azathioprine equivalent dose (mg/d) 75 (50) 100 (25) 0.448
Leukopenia 1 (20%) 25 (24.5%) 1.000
Idiosyncratic reaction 1 (20%) 6 (5.9%) 0.292
Treatment interruption 1 (20%) 29 (28.4%) 0.532